Search company, investor...
Senseonics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Loan | IPO

Total Raised


Market Cap


Stock Price




About Senseonics

Senseonics, formerly Sensors for Medicine and Science, develops and commercializes transformative glucose monitoring products that enable people with diabetes to live with ease. SMSI is developing a fully implantable, continuous glucose monitoring system designed to be highly accurate and biocompatible throughout its long sensor life. SMSI utilizes fluorescence sensing technology which is intended to provide people with diabetes with an accurate and easy-to-use system for better diabetes management.

Senseonics Headquarters Location

20451 Seneca Meadows Parkway

Germantown, Maryland, 20876,

United States

+1 301 515 7260

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Senseonics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Senseonics is included in 6 Expert Collections, including Wearable Computing.


Wearable Computing

411 items

Wearable computing is broadly defined as companies developing devices worn or placed on the body that are equipped with technology, which can range from wearable medical devices to AR/VR headsets to GPS pet collars.


Medical Devices

8,782 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



1,750 items


Smart Home & Consumer Electronics

1,198 items

This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.


Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,901 items

Senseonics Patents

Senseonics has filed 133 patents.

The 3 most popular patent topics include:

  • Analytical chemistry
  • Sensors
  • Chromatography
patents chart

Application Date

Grant Date


Related Topics




Dosage forms, Medical equipment, Drug delivery devices, Analytical chemistry, Implants (medicine)


Application Date


Grant Date



Related Topics

Dosage forms, Medical equipment, Drug delivery devices, Analytical chemistry, Implants (medicine)



Latest Senseonics News

The Worldwide Next Generation Diabetes Therapy and Drug Delivery Industry is Expected to Reach $28 Million by 2030 -

Sep 23, 2022

Senseonics Holdings, Inc. The next generation diabetes therapy and the drug delivery devices are the advanced form of diabetic products that improve the quality of life of diabetic patients. These products help in the management of the blood glucose level of diabetic patient in minimally invasive manner. Oral and inhalable insulin introduce a different mode of insulin delivery in diabetic patients. It is a painless mode of introducing insulin than the injectable insulins, reducing the risk of skin irritation caused due to needles. In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. Advanced diabetic therapy in the form of insulin patches, continuous glucose monitoring systems (CGMS), and artificial pancreas helps to improve management of blood sugar level and reduces the risk of any diabetic-related complications. The main factors that drive the growth of the next generation diabetes therapy and the drug delivery market include, the benefits of using these advanced devices over conventional products and rise in the healthcare expenditure. In addition, rise in incidences of diabetes globally and increase in the disposable income among the diabetic patients, further supplement the global next generation diabetes therapy and drug delivery market growth. Conversely lack of awareness, cost restrains in the developing regions, and less variability in products are expected to obstruct the growth of the market during forecast years. On the other hand, development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to offer profitable opportunities for the growth of the market during the forecast period. The global next generation diabetes therapy and drug delivery market is segmented based on product, demographic, indication, end user, and region. On the basis of product, it is classified into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. On the basis of demographics, it is bifurcated into adult population (>14 years) and child population (?14 years). By indication, it is divided into type 1 diabetes and type 2 diabetes. On the basis of end users, it is categorized into diagnostics/clinics, ICUs, and home healthcare. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Key Benefits For Stakeholders This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the next generation diabetes therapy and drug delivery market analysis from 2020 to 2030 to identify the prevailing next generation diabetes therapy and drug delivery market opportunities. The market research is offered along with information related to key drivers, restraints, and opportunities. Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network. In-depth analysis of the next generation diabetes therapy and drug delivery market segmentation assists to determine the prevailing market opportunities. Major countries in each region are mapped according to their revenue contribution to the global market. Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players. The report includes the analysis of the regional as well as global next generation diabetes therapy and drug delivery market trends, key players, market segments, application areas, and market growth strategies. Key Market Segments Child Population (14 years)

Senseonics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Senseonics Rank

  • When was Senseonics founded?

    Senseonics was founded in 1997.

  • Where is Senseonics's headquarters?

    Senseonics's headquarters is located at 20451 Seneca Meadows Parkway, Germantown.

  • What is Senseonics's latest funding round?

    Senseonics's latest funding round is Loan.

  • How much did Senseonics raise?

    Senseonics raised a total of $143.4M.

  • Who are the investors of Senseonics?

    Investors of Senseonics include Paycheck Protection Program, New Enterprise Associates, Delphi Ventures, Oxford Finance, Anthem Capital and 5 more.

  • Who are Senseonics's competitors?

    Competitors of Senseonics include Innara Health, WaveForm Diabetes, Posit Science, NeuroLutions, PhysioSonics, Biorasis, ReGear Life Sciences, Micronics Microfluidics, TransCorp, Eyesense and 19 more.

You May Also Like

Biowatch Medical

Biowatch Medical is the producer of "Sentry" a wearable vital signs monitor


Vytrace Corporation is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. Vytrace Corporation is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.


Speckodyne Corp aims to be a provider of continuous real-time blood coagulability monitoring technology in Operation Room, Catheterization Lab or Intensive Care Unit settings. Based on a approach developed at UCF's College of Optics & Photonics, Speckodyne's blood coagulability monitor uses optical fiber and solid-state optics technology, leading to a robust, relatively inexpensive design that can be easily integrated with existing interventional devices such as catheters and guidewires, as well as bed-side or laboratory equipment.

Mercator MedSystems

Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.

Rafael Medical Technologies

Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.


Kyphon develops and markets medical devices designed to restore spinal function using minimally invasive technologies. The company's KyphX(R) line of products is used in balloon kyphoplasty, a minimally invasive procedure to treat spinal fractures caused by osteoporosis or cancer. More information about the company can be found at

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.